LIWANLI Innovation Co Ltd
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry in Taiwan and internationally. The company offers Vigoway and powder collection products for male, female, elderly, and children. Its products include anti-aging desire, pro-active nutrients capsules, black elderberry powder, probiotic enzymes, oral care tablets, resveratrol red grape extract, algae DHA soft gels, shea butte… Read more
Market Cap & Net Worth: LIWANLI Innovation Co Ltd (3054)
LIWANLI Innovation Co Ltd (TW:3054) has a market capitalization of $212.80 Million (NT$7.04 Billion) as of March 18, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #21286 globally and #1158 in its home market, demonstrating a 94.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LIWANLI Innovation Co Ltd's stock price NT$87.30 by its total outstanding shares 80651041 (80.65 Million).
LIWANLI Innovation Co Ltd Market Cap History: 2015 to 2026
LIWANLI Innovation Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $60.35 Million to $212.80 Million (13.72% CAGR).
LIWANLI Innovation Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LIWANLI Innovation Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.61x
LIWANLI Innovation Co Ltd's market cap is 0.61 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $60.35 Million | $834.91 Million | -$103.45 Million | 0.07x | N/A |
| 2016 | $61.79 Million | $323.10 Million | $62.80 Million | 0.19x | 0.98x |
| 2017 | $53.16 Million | $348.21 Million | $81.91 Million | 0.15x | 0.65x |
| 2018 | $64.84 Million | $185.51 Million | $891.00K | 0.35x | 72.77x |
| 2019 | $69.47 Million | $129.78 Million | $2.78 Million | 0.54x | 24.97x |
| 2020 | $58.50 Million | $276.88 Million | -$13.61 Million | 0.21x | N/A |
| 2021 | $62.89 Million | $47.81 Million | $45.56 Million | 1.32x | 1.38x |
| 2022 | $48.63 Million | $33.99 Million | -$120.91 Million | 1.43x | N/A |
| 2023 | $51.19 Million | $38.89 Million | $5.10 Million | 1.32x | 10.03x |
| 2024 | $60.09 Million | $99.16 Million | -$32.07 Million | 0.61x | N/A |
Competitor Companies of 3054 by Market Capitalization
Companies near LIWANLI Innovation Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to LIWANLI Innovation Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
LIWANLI Innovation Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, LIWANLI Innovation Co Ltd's market cap moved from $60.35 Million to $ 212.80 Million, with a yearly change of 13.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$212.80 Million | +169.03% |
| 2025 | NT$79.10 Million | +31.64% |
| 2024 | NT$60.09 Million | +17.38% |
| 2023 | NT$51.19 Million | +5.26% |
| 2022 | NT$48.63 Million | -22.67% |
| 2021 | NT$62.89 Million | +7.50% |
| 2020 | NT$58.50 Million | -15.79% |
| 2019 | NT$69.47 Million | +7.14% |
| 2018 | NT$64.84 Million | +21.96% |
| 2017 | NT$53.16 Million | -13.96% |
| 2016 | NT$61.79 Million | +2.38% |
| 2015 | NT$60.35 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of LIWANLI Innovation Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $212.80 Million USD |
| MoneyControl | $212.80 Million USD |
| MarketWatch | $212.80 Million USD |
| marketcap.company | $212.80 Million USD |
| Reuters | $212.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.